PO Opioids/NSAIDs Flashcards
1
Q
3 Major Sites of Action of Opioids
A
Brain, Spinal Cord and Periphery:
- Brain (supraspinal): Opioids work pre- and post- synaptically to activate descending inhibitory pathways
- Spinal cord (spinal): Directly on dorsal horn of spinal cord
- Periphery: Peripheral terminals of nociceptive neurons
2
Q
Opioids are used in Anesthesia for:
A
- Attenuate SNS response to noxious stimuli
- Adjunct to inhaled agents during anesthesia
- Sole anesthetic (fentanyl/sufent/morphine- cardiac anesthesia, critically ill pts)
- Peri-op and post-op control of pain
3
Q
Unique Opioid Characteristics set them apart from other Analgesics
A
- Moderate to severe pain
- No max dose or ceiling effect
- Tolerance can develop w/ chronic use
- Tolerance associated w/ physical dependence but not necessarily w/ psychological dependence
- Cross-tolerance
- Produce analgesia w/out loss of
- Touch
- Proprioception
- Consciousness (in smaller doses)
4
Q
Opioid Classification
A
- Naturally occurring
- Morphine and codeine
- Semisynthetic: Analogs of morphine
- Heroin and Dihydromorphone
- Synthetic
- Exogenous, 4 groups
- Further classified into:
- Agonist, Partial agonist, Mixed agonist/antagonis, Antagonist
5
Q
Opioids: Mechanism of Action:
Post-synaptic
A
- Activate stereospecific G-protein coupled receptors
-
Post-synaptic - directly decreases neurotransmission
- Increased K+ conductance (hyperpolarization)
- Ca++ channel inactivation (decreased NT release)
- Modulation of phosphoinositide – signaling cascade and phospholipase C
- Inhibit adenylate cyclase (decreased cAMP)
-
Post-synaptic - directly decreases neurotransmission
6
Q
Opioids: Mechanism of Action:
Pre-synaptic
A
- Activate stereospecific G-protein coupled receptors
-
Pre-synaptic- inhibits release of excitatory NT’s
- ↓ release of Ach, DA, norepi, substance P
-
Pre-synaptic- inhibits release of excitatory NT’s
7
Q
Opioid Receptors
A
- Receptors: mu, kappa, and delta
- Theory: synthetic opioids mimic action of endogenous opioids by binding to opioid receptors
- Activate endogenous pain modulating systems
- Variable affinity and efficacy at different receptors types among different drugs in this class
8
Q
Mu receptor
A
- Subtypes mu-1 and mu-2
- Mu-3 receptors thought to be involved in immune process
- All endogenous and exogenous agonists act on mu receptors
- Mu receptors in brain, periphery and spinal cord
9
Q
Mu-1 receptor
A
- Mu-1 receptor
- Supraspinal, spinal, and peripheral analgesia
- Low abuse potential
- Euphoria
- Miosis
- Bradycardia
- Hypothermia
- Urinary retention
- All endogenous and synthetic opioid agonists act on these receptors
10
Q
Mu-2 Receptor
A
- Mu-2 Receptor
- Spinal analgesia (also some supraspinal)
- Physical dependence
- Hypoventilation
- Constipation
- All endogenous and exogenous agonists act on these receptor
11
Q
Kappa Receptor
A
- Kappa Receptor
- Supraspinal, spinal and peripheral analgesia
- Low abuse potential
- Dysphoria
- Sedation
- Miosis
- Diuresis
- Dynorphins act on these receptors
- Opioid agonist-antagonists often have principle actions at kappa receptor
12
Q
Delta Receptor
A
- Delta Receptor
- Supraspinal, spinal, and peripheral analgesia
- Physical dependence
- Hypoventilation
- Constipation
- Urinary retention
- Enkephalins work on these receptor
13
Q
Genetics of CYP450 System and Influence on Opioids
A
-
CYP2D6 = 5 common mutations can alter metabolism of:
- Codeine, oxycodone, hydrocodone, and methadone
- Unpredictable pharmacokinetics and ½ lives
- Fentanyl’s metabolism least likely to be impacted by genetic variability in surgical population = predictable pharmacokinetics
- Rate of metabolism may influence side effect rate
- Studies indicate ultra-rapid metabolizers at ↑ r/f PONV
14
Q
Systemic Effects of Opioids
A
- Many systemic effects similar among opioids
- Although different opioids are active at different receptors to different degrees
-
Variable SE and efficacy profiles
- Variance in chemical structures
- Morphine = prototype
15
Q
CNS Effects
A
- Analgesia
- Euphoria
- Drowsiness/sleep
- Miosis
- Nausea- chemoreceptor trigger zone
- Does not produce amnesia
16
Q
Pulmonary Effects
A
- ↓RR and ↑TV
- At higher doses = ↓ RR & TV → leading to apnea
- ↓ response to CO2 and hypoxia
17
Q
GI Effects
A
- N/V
- Decreased gastric emptying
- Direct stimulation of chemoreceptor trigger zone on floor of 4th ventricle
- Partial dopamine agonist?
- Balanced by depression of medullary vomiting center
18
Q
Pruritis
A
- Cause unknown
- Occurs primarily on face particularly nose
- “fentanyl nose itch”
- Histamine release most probable cause w/ some (MSO4)
19
Q
Morphine
A
- Severe acute pain almost always IM or IV admin
- PO used for chronic pain and CA pain
- Slow release formulations available – delayed onset 3-5 hrs (not used pre-op/intra-op much)
- Considerable first pass effect
- E½t 3-4 hrs converted to active metabolite (morphine -6-glucuronide)
20
Q
Codeine (3-methylmorphine)
A
-
Mild Pain Relief
- Better for cough (lower dose) than pain relief
- PO
- E½t = 3 hrs
-
Prodrug: 10% is metabolized by CYP2D6 to its active form
- Active form = morphine
- Remaining drug demethylated to inactive metabolite
- 10% Caucasians, 30% Asians lack 2D6 = no analgesic effect
- Antitussive effect remains even w/out conversion
21
Q
Hydrocodone
A
- AKA – Vicodan
- PO
- Always combined w/ either ASA, antihistamine, acetaminophen, ibuprofen
- Used for chronic pain
- Analgesic and antitussive
- High abuse potential
22
Q
Oxycodone
A
- AKA Oxycontin, Percocet, Percodan
- oxycontin -sustained release preparation
- PO
- Moderate to severe pain; useful for chronic and post-op pain
- Also in combo w/ ASA or acetaminophen
- No active metabolites - safer in renal dysfunction
- High abuse potential
23
Q
Methadone
A
- PO, IV, SubQ
- Synthetic
- Long E½t- 8-59 hrs or 13-100 hrs (sources vary)!
- No active metabolites - safer w/ renal dysfunction
- Opioid addiction treatment (maintenance) dosed QD
- Chronic pain syndrome treatment: doses BID or TID (q4-8 hr)
- Neuropathic pain
- At r/f severe resp depression 2° to prolonged & unpredictable E½t
24
Q
Tolerance to Opioids
A
- Tolerance common w/ chronic use (after 2-3 wks of use)
- Cross-tolerance exists among all full agonists but not complete
- When switching to another opioid, start w/ ½ or less of customary equianalgesic dose
- Switching opioid-tolerant pts to methadone may improve pain relief
- Tolerance to sedative and emetic effects develop rapidly, but not constipation
- A stimulant laxative +/- a stool softener should be started early (senna/docusate)
25
Q
Tolerance to Opioids:
Patient notices…
A
- Pt notices:
- Reduction in adverse effects
- Shorter duration of analgesia
- Decreased effectiveness of each dose
-
Tolerance to most adverse effects include:
- Respiratory and CNS depression
- Can be surmounted by increasing dose
26
Q
Dependence
A
- Physical dependence causes abstinence symptoms w/ sudden d/c
- Clinically significant dependence develops only after several wks of chronic tx
- Addiction involves psychological dependence and biologic and social factors
- CA pain and acute pain pts rarely experience euphoria; even more rarely develop psychological dependence or addiction
27
Q
Dosage (PO)
A
- Dose varies widely from pt to pt
- No min or max dose except limitation by dose of acetaminophen or aspirin
- Use dose required to maintain optimum pain relief w/ tolerable SE’s
- After initial titration w/ short-acting opioid in first 12-24 hrs, dose determination by around-clock dosing recommended
- Use sustained release formulas in chronic pain
- Immediate release doses that are 10 to 15% of total daily dose should be used for breakthrough pain
- PCA, given IV, SQ or other routes now widely used when PO route not feasible